SciClone Pharmaceuticals (6600.HK)
Company Info
Highlights
HK$11.80B
10.12
HK$18.16 - HK$18.72
HK$16.71
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
Loading data...
Returns By Period
6600.HK
N/A
N/A
N/A
N/A
N/A
N/A
^GSPC (Benchmark)
-3.77%
7.44%
-5.60%
8.37%
14.12%
10.46%
Monthly Returns
The table below presents the monthly returns of 6600.HK, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | -20.26% | 17.30% | 23.20% | 11.85% | 3.12% | 1.19% | 0.00% | 34.48% | |||||
| 2023 | 14.35% | 4.11% | 3.75% | 15.82% | -11.47% | 4.35% | 2.66% | -12.57% | 5.60% | 3.10% | 32.04% | 2.35% | 74.55% |
| 2022 | -2.89% | -6.55% | 3.57% | 1.97% | -0.23% | 9.71% | -10.80% | -7.99% | -13.31% | -7.27% | 9.93% | 31.38% | -0.05% |
| 2021 | -17.23% | 1.41% | -6.72% | 1.22% | -23.36% | -14.97% | 7.11% | 1.73% | -14.27% | -4.63% | -53.99% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
With an overall rank of 92, 6600.HK is among the top 8% of stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for SciClone Pharmaceuticals (6600.HK) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
SciClone Pharmaceuticals provided a 0.00% dividend yield over the last twelve months, with an annual payout of HK$0.00 per share.
| Period | TTM | 2023 | 2022 |
|---|---|---|---|
| Dividend | HK$0.00 | HK$0.39 | HK$0.35 |
Dividend yield | 0.00% | 2.80% | 4.22% |
Monthly Dividends
The table displays the monthly dividend distributions for SciClone Pharmaceuticals. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | |||||
| 2023 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.39 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.39 |
| 2022 | HK$0.35 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.35 |
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the SciClone Pharmaceuticals. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the SciClone Pharmaceuticals was 68.49%, occurring on Oct 28, 2022. Recovery took 349 trading sessions.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -68.49% | Mar 4, 2021 | 409 | Oct 28, 2022 | 349 | Apr 2, 2024 | 758 |
| -0.65% | May 28, 2024 | 2 | May 29, 2024 | 2 | May 31, 2024 | 4 |
| -0.64% | Jun 11, 2024 | 2 | Jun 12, 2024 | 6 | Jun 20, 2024 | 8 |
| -0.55% | Apr 16, 2024 | 11 | Apr 30, 2024 | 2 | May 3, 2024 | 13 |
| -0.45% | Apr 8, 2024 | 2 | Apr 9, 2024 | 3 | Apr 12, 2024 | 5 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of SciClone Pharmaceuticals over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how SciClone Pharmaceuticals is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for 6600.HK, comparing it with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, 6600.HK has a P/E ratio of 10.1. This P/E ratio is in line with the industry average, suggesting the stock may be fairly valued relative to its earnings.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for 6600.HK relative to other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, 6600.HK has a P/S ratio of 3.7. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for 6600.HK in comparison with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, 6600.HK has a P/B value of 3.4. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |